Martin J. van den Bent

Research interests

Publications

• Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

  New England Journal of Medicine · 2023 · 10.1056/nejmoa2304194

• Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

  Journal of Clinical Oncology · 2021 · 10.1200/jco.21.02314

• Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

  Neuro-Oncology · 2020 · https://doi.org/10.1093/neuonc/noaa106

• EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

  Nature Reviews Clinical Oncology · 2020 · https://doi.org/10.1038/s41571-020-00447-z

• Molecular targeted therapy of glioblastoma

  Cancer Treatment Reviews · 2019 · https://doi.org/10.1016/j.ctrv.2019.101896

• EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx221

• European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30194-8

• Lomustine and Bevacizumab in Progressive Glioblastoma

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1707358

• Response assessment criteria for brain metastases: proposal from the RANO group

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)70057-4

• Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

  Neuro-Oncology · 2015 · 10.1093/neuonc/nov095

• Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70379-1

• EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70011-7

• MGMT testing—the challenges for biomarker-based glioma treatment

  Nature Reviews Neurology · 2014 · 10.1038/nrneurol.2014.100

• High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2014 · 10.1093/annonc/mdu050

• Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70314-6

• Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.47.2464

• Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2012.43.2229

• Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

  The Lancet Oncology · 2011 · 10.1016/s1470-2045(11)70057-2

• Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.26.3541

• MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

  Nature Reviews Neurology · 2009 · 10.1038/nrneurol.2009.197

• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

  The Lancet Oncology · 2009 · https://doi.org/10.1016/s1470-2045(09)70025-7

• Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology

  Cancer Research · 2009 · 10.1158/0008-5472.can-09-2307

• Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

  The Lancet Oncology · 2008 · 10.1016/s1470-2045(08)70125-6

• Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial

  Journal of Clinical Oncology · 2006 · 10.1200/jco.2005.04.6078

• Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.13.524

• Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

  New England Journal of Medicine · 2005 · https://doi.org/10.1056/nejmoa043330

• Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

  The Lancet · 2005 · 10.1016/s0140-6736(05)67070-5

• Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma

  Journal of Clinical Oncology · 2002 · 10.1200/jco.2002.08.121

Current projects

No projects listed.